SG Americas Securities LLC Invests $542,000 in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

SG Americas Securities LLC bought a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 19,228 shares of the company’s stock, valued at approximately $542,000.

Several other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Fulcrum Therapeutics by 15.0% during the 2nd quarter. BlackRock Inc. now owns 1,297,445 shares of the company’s stock worth $13,598,000 after acquiring an additional 168,866 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Fulcrum Therapeutics by 7.6% during the 2nd quarter. Vanguard Group Inc. now owns 907,035 shares of the company’s stock worth $9,505,000 after acquiring an additional 63,840 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Fulcrum Therapeutics by 5.1% during the 2nd quarter. Millennium Management LLC now owns 625,635 shares of the company’s stock worth $6,557,000 after acquiring an additional 30,574 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth about $4,302,000. Finally, Geode Capital Management LLC boosted its stake in shares of Fulcrum Therapeutics by 25.2% during the 2nd quarter. Geode Capital Management LLC now owns 356,592 shares of the company’s stock worth $3,737,000 after acquiring an additional 71,855 shares in the last quarter. 93.94% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:FULC opened at $13.92 on Friday. The business’s 50 day moving average price is $16.45 and its 200-day moving average price is $18.95. The firm has a market capitalization of $564.44 million, a PE ratio of -5.92 and a beta of 1.36. Fulcrum Therapeutics, Inc. has a 1 year low of $6.85 and a 1 year high of $33.10.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Thursday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.07. The firm had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.94 million. Fulcrum Therapeutics had a negative return on equity of 53.21% and a negative net margin of 409.62%. During the same period in the previous year, the company posted ($0.70) earnings per share. On average, analysts forecast that Fulcrum Therapeutics, Inc. will post -2.37 earnings per share for the current year.

Separately, Zacks Investment Research lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $35.57.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC).

Institutional Ownership by Quarter for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.